PRMENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Prime Medicine, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.83+0.36 (+10.37%)
Close on Oct 19, 2026
- Market cap
- $678.77M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Operating margin
-4498.1%−4480.2 pts over 5 years
Net margin
-4342.4%−4277.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +55.3% | – | -2.3% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 2623.1% | -146.8% | |
| Return on assets | – | – | -62.8% | |
| Current ratio | – | – | 4.84 | |
| Capex to revenue | – | 12.3% | 97.8% | |
| Diluted shares | – | 3M | 149M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Prime Medicine generated $616.75M from operations and spent $40.79M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$616.75M
Used
$40.79M
Capital expenditure$40.79M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-4342.4%
×Asset turnover0.01×
×Equity multiplier2.34×
=Return on equity, FY2025-146.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -4342.4% | 0.01× | 2.34× | -146.8% |
| FY2024 | -6566.6% | 0.01× | 1.72× | -136.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$201.14M
- Cash generatingOperating cash flow above zero-$162.56M
- Return on assets improvedROA up on the prior year-101.0% → -67.6%
- Earnings backed by cashOperating cash flow above net income-$162.56M vs -$201.14M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.58 → 4.84
- No dilutionShare count did not rise119M → 149M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.02 → 0.02